NextFin News - Teva Pharmaceutical Industries' chief executive says the company's ordinary shares now trade directly on the New York Stock Exchange, ending the American Depositary Shares structure that has intermediated foreign issuers into U.S. markets for decades. Richard Francis, Teva's president and CEO, framed the Sept. 14, 2026 move in an interview as the latest milestone in the Israeli drugmaker's "Pivot to Growth" turnaround, saying the direct listing is expected to broaden investor access to the stock. The shares continue to trade under the same ticker, TEVA, on both the NYSE and the Tel Aviv Stock Exchange.
The announcement completes Teva's planned transition away from its ADS program, under which U.S. investors held depositary receipts issued by a bank rather than the underlying ordinary shares. The change is more than a listing technicality: it removes a depositary layer that historically carried fees, voting frictions, and, most importantly for Teva's capital strategy, eligibility exclusions for index funds and institutional mandates barred from holding depositary instruments. The timing is deliberate. Teva is coming off a string of credit upgrades that returned it to investment-grade territory, and the company is leaning on a fast-growing trio of innovative brands — AUSTEDO, AJOVY, and UZEDY — that collectively grew more than 40% year over year on a year-to-date basis, with approximately $3.7 billion in expected 2026 revenue. The question for investors is whether a cleaner share structure can actually widen Teva's ownership base, or whether it is a well-timed cosmetic change that leaves the real work — executing the turnaround — untouched.
Why the ADS Wrapper Mattered, and Why Shedding It Is Structural, Not Cyclical
For decades, non-U.S. companies accessed American capital through American Depositary Receipts, a mechanism created when cross-border settlement was difficult. A depositary bank holds the foreign shares and issues receipts against them. That structure solved a mid-20th-century problem but introduced three persistent costs: a depositary fee that drags on total return, a voting-and-corporate-action layer that separates economic ownership from legal control, and, critically, mandate exclusions. Many U.S. pension funds, state retirement systems, and index-tracking vehicles are prohibited, by charter, by policy, or by index rules, from holding depositary receipts. They can own only ordinary shares listed on a U.S. national exchange.
Teva's move to direct ordinary-share trading is therefore a regime change, not a cyclical fluctuation. A cyclical move is mean-reverting: a cheap valuation that normalizes, a temporary supply squeeze that eases. A structural change alters the rules of the game and does not revert on its own. Once Teva's ordinary shares trade directly on the NYSE, they do not "become ADSs again." The eligibility gate is permanently opened. The precedent is instructive: AstraZeneca completed an almost identical transition in February 2026, delisting its ADSs from Nasdaq and moving its ordinary shares to the NYSE as part of a shareholder-approved plan to unify its listing structure. AstraZeneca's advisers argued the direct listing created a more potent "acquisition currency" — stock-swap deals are far easier to negotiate when the shares on offer are a single, globally recognized ordinary class rather than a complex depositary receipt.
The evidence that this is structural is threefold. First, the change is legal and permanent, a listing-structure migration rather than a price move. Second, the driver is durable: the universe of U.S. institutional capital constrained by depositary exclusions is not going to reverse. Third, the mechanism is not self-correcting; Teva would have to actively re-create an ADS program to undo it, and there is no reason to. A cyclical claim would require mean-reversion evidence and a short-term driver, and neither applies here. This is a capital-structure regime shift, and it should be judged on that timescale.
"Our move to a direct ordinary share listing is an important step in strengthening our position in the U.S. capital markets," said Eli Kalif, Teva's executive vice president and chief financial officer. "Together with our recent return to investment-grade credit ratings from all three major ratings agencies, this milestone demonstrates the strength of our financial transformation, expands our access to investors and enhances our ability to invest for long-term growth."
The Mechanics: What the Depositary Layer Actually Costs
To understand what Teva is shedding, it helps to name the friction precisely. An ADS is a negotiable certificate issued by a depositary bank that represents a claim on a specific number of the issuer's ordinary shares, which the bank holds in custody in the home market. The investor owns the receipt, not the share. That separation creates a fee: depositary banks charge an ADS fee, typically collected by deducting it from dividends or billing the registered holder, and the fee is a persistent drag on total return that compounds silently over years. It also creates operational friction. Corporate actions, proxy voting, and dividend conversions all run through the depositary's timetable rather than the issuer's, which can delay or dilute shareholder voice.
But the fee drag is the smallest of the three costs. The binding constraint is eligibility. A growing share of U.S. institutional assets sits inside mandates that explicitly exclude depositary receipts — some state pension plans, some defined-contribution default funds, some quantitative and risk-parity vehicles whose investment guidelines define eligible securities as ordinary shares listed on a national exchange. For those pools, Teva-as-ADS simply did not exist as a buyable name, regardless of how attractive the fundamentals were. The direct listing converts Teva from "not eligible" to "eligible" overnight. That is a one-way door, and it is why the market should treat this as a structural change to the shareholder base rather than a trading event.
There is a second-order benefit that management did not lead with but that follows directly from the mechanics: a unified share class is better acquisition currency. When a company pays for a takeover with stock, the seller wants a liquid, universally recognizable instrument. A direct ordinary listing on the NYSE puts Teva's shares in the same form as its U.S. biopharma peers, removing a friction that would otherwise be priced into any future stock-swap transaction. It is not the reason for the move, but it is a real option value embedded in the new structure.
The Second-Order Question: Access Is an Enabler, Not the Value Engine
The first-order effect of the listing change is mechanical: the same economic claim now trades in a form more funds can hold. The second-order question is whether that broadened access actually translates into a higher, more stable shareholder base, and here the market is pricing the conventional wisdom too confidently. The consensus read is simple and already stated: more eligible buyers equals a higher multiple. But that chain has a weak link. Access is a necessary condition for ownership, not a sufficient one. A fund that can hold TEVA will hold it only if the risk-adjusted return case clears its hurdle, and Teva's case rests on execution, not on listing mechanics.
Trace the transmission chain one step further. A direct listing removes frictions, which can reduce the liquidity discount embedded in the shares. A smaller liquidity discount lowers the cost of equity. A lower cost of equity supports a higher valuation multiple, but only if earnings are credible. And Teva's earnings credibility is exactly where the tension lies. The company reported $17.3 billion in 2025 revenue, up 4%, with earnings per share of $2.83, but its 2026 guidance of $16.4 billion to $16.8 billion in revenue and $2.57 to $2.77 in EPS came in below analyst expectations, and the stock fell on both the Tel Aviv and U.S. markets when those numbers were released. A listing change does not fix a guidance miss. The market may read the NYSE move as a signal of management confidence, a "we have nothing to hide, bring on the owners" gesture, but signals are cheap and quarterly prints are not.
The real value engine is the Pivot to Growth, and the listing is the wrapper around it. Teva's three flagship innovative brands are the proof point the company wants investors to focus on: more than 40% collective year-over-year growth year to date, with approximately $3.7 billion expected in 2026 revenue. Beyond them sits a pipeline the company values at more than $10 billion in peak-revenue potential. If those numbers hold, the direct listing amplifies the rerating by widening the buyer pool. If they do not, the listing is a door that opened onto an empty room. This is the asymmetry investors should hold in mind: the listing changes who can own Teva; only the drugs change what Teva is worth.
The Counter-Thesis: A Listing Change Is Not a Catalyst, and the Credit Story Is Incomplete
The strongest argument against reading this as a genuine catalyst is straightforward: listing mechanics rarely move stocks on their own, and the market has a long memory of "strategic" restructurings that delivered no alpha. Empirically, exchange migrations and ADS-to-ordinary conversions produce little durable price impact absent a concurrent fundamental inflection. The burden of proof is on Teva to show that ownership actually broadened, and that metric will not be visible for two to three quarters, until regulatory filings reveal whether the U.S. institutional holder count and assets-under-management exposure rose. Until then, the "broadened access" claim is an assertion, not an outcome.
There is also a subtler hole in the credit narrative the CFO invoked. Teva's management says it has returned to investment grade "across all three major ratings agencies." Independent reporting confirms that Fitch upgraded Teva to BBB- with a stable outlook in May 2026, its third upgrade in under two years, and that Moody's raised the company to Baa3, also stable, in August 2026, citing stronger earnings, improving margins, solid cash flow, and continued debt reduction. But as of May, S&P Global Ratings still carried Teva at BB+, one notch below investment grade, with a stable outlook. If S&P has since upgraded, the company's claim holds; if not, the "all three" framing overstates the credit turnaround. Investors should treat the ratings narrative as partially verified and watch for S&P's next action. A ratings story that is two-thirds complete is not the same as a fully restored investment-grade balance sheet.
The falsifying signal is concrete. If flagship-brand growth decelerates sharply, with collective year-over-year growth falling below roughly 20%, or if ownership filings two to three quarters from now show no measurable increase in the U.S. institutional holder base, the "broadened access creates value" thesis is materially weakened. Conversely, if S&P does not follow Fitch and Moody's into investment-grade territory, the credit-recovery pillar of the story is incomplete regardless of the listing. A structural change to the share class cannot substitute for a structural change to the earnings trajectory.
What to Watch, by Time Horizon
Short term (sentiment and liquidity): the direct listing is a positive technical development that removes a structural overhang and may narrow the liquidity discount. But do not expect the listing itself to drive the tape. The near-term price action will be dictated by the same factors that moved the stock earlier in 2026: quarterly prints versus guidance, and whether the market looks past a soft 2026 outlook to the innovative-drug growth underneath. Watch trading volume and bid-ask spreads in the first weeks for early evidence that the new share form is attracting incremental flow.
Medium term (fundamentals): this is where the story is won or lost. Watch the three flagships. AUSTEDO, AJOVY, and UZEDY must sustain their collective growth trajectory toward and beyond the $3.7 billion run-rate. Watch margins and free cash flow as debt reduction continues, because the ratings upgrades were earned on exactly those metrics. And watch the pipeline: assets with more than $10 billion in peak-revenue potential mean nothing until regulatory approvals and launches convert them into revenue. The company has flagged multiple near-term pipeline and commercial catalysts; those dates are the real calendar to watch, not the listing date.
Long term (structural): the direct ordinary listing is a permanent upgrade to Teva's capital structure and aligns it with a broader 2026 trend of non-U.S. issuers, AstraZeneca among them, choosing direct U.S. listings over depositary wrappers. Over a multi-year horizon, this should support a deeper, more diversified shareholder base and a lower cost of capital. But structural advantages compound slowly; they do not rescue weak fundamentals.
Scenarios
- Base case: flagship brands grow in line with the $3.7 billion expectation, margins expand, and the direct listing gradually widens the U.S. institutional holder base over four to six quarters. The stock earns a modest rerating as the liquidity discount compresses.
- Upside case: the innovative portfolio accelerates beyond expectations, S&P upgrades Teva to investment grade, and ownership filings show a step-change in eligible-fund participation. The listing then acts as an amplifier, and Teva's valuation gap versus integrated biopharma peers narrows meaningfully.
- Downside case: flagship growth decelerates, the 2026 guidance miss proves to be a pattern rather than a one-off, and ownership data shows no broadening. In that scenario the NYSE listing becomes a footnote, a well-executed technical change that could not substitute for fundamental delivery.
The verdict: Teva's move to trade ordinary shares directly on the NYSE is a genuine structural improvement to its capital structure, and it arrives at the right moment in the company's turnaround. But a listing is a door, not a destination. The direct listing removes the frictions that kept some owners out; it does not give them a reason to come in. That reason has to be earned, quarter by quarter, by the Pivot to Growth.
Explore more exclusive insights at nextfin.ai.
